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Abstract: Thymomas are tumors of thymic epithelial cells. They
associate more often than any other human tumors with various
autoimmune diseases; myasthenia gravis is the commonest, occur-
ring in 10–50% of thymoma patients, depending on the World
Health Organization-defined histologic subtype. Most thymomas
generate many polyclonal maturing T lymphocytes but in disorga-
nized microenvironments Failure to induce self-tolerance may be a
key factor leading to the export of potentially autoreactive CD4
progeny, thus predisposing to autoimmune diseases. Normally, the
master Autoimmune Regulator promotes expression of peripheral
tissue-restricted antigens such as insulin by medullary thymic epi-
thelial cells and induction of tolerance to them. The failure of95%
of thymomas to express autoimmune regulator is another feature
potentially contributing to autoimmunity.
Key Words: Thymoma, AIRE, APECED, APS-1, Myasthenia
gravis.
(J Thorac Oncol. 2010;5: S266–S272)
The normal thymus generates maturing T lymphocytesfrom bone marrow-derived progenitors, and screens them
for autoreactivity. Those that are potentially autoaggressive
are deleted in the medulla—against major histocompatibility
complex (MHC) antigens (including cross-presented peptides
of autoantigens) by dendritic cells (DC) and against tissue-
restricted antigens (TRAgs) by medullary thymic epithelial
cells (mTECs) that express them under the control of auto-
immune regulator (AIRE) (or perhaps other analogous regu-
lators). A minority of the latter group escapes deletion and
matures into the natural regulatory T cell (Treg) subset. Like
other descendants, Tregs then emigrate into the peripheral
pool, where they maintain self-tolerance and immunity
against infection.
Thymomas
Thymomas are histologically diverse tumors of thymic
epithelial cells (TECs). The new World Health Organization
(WHO) classification divides them into types A, AB, B1, B2,
and B3 (Figure 1).1,2 By contrast, thymic carcinomas are
named after their morphologically similar extrathymic coun-
terparts and no longer as “type C thymomas.” The local
extension of thymomas and their metastatic spread is de-
scribed by the staging system first suggested by Masaoka3 or
its slightly modified version.2 Stage, in addition to complete
resection, have proved to be the best single prognostic marker
and an essential indicator for guiding therapy.4–6 Update
articles dealing with the classification and staging of thymo-
mas are published in this monograph (Masaoka A; Kondo K).
In contrast with other cancers (including thymic carci-
nomas), 80% of thymomas are thymopoietic and generate
“single positive” CD4 and CD8 T cells, often in vast
number, but in disordered microenvironments. This thymo-
poiesis varies according to the thymoma subtype: it is (by
definition) minimal or even apparently absent in type A
thymomas; it is prominent but patchy and relatively ineffi-
cient in type AB, generating few mature single CD4 or
CD8 T cells; it is abundant and appearing almost normal in
types B1 and B2; and it is sparse but phenotypically quite
normal in type B3.7,8 Thymomas of types A and AB almost
never metastasize; although slow-growing, types B2 and B3
can be invasive both locally and by the pleura, although
blood-borne metastases are very rare.6
With the exception of some type A thymomas, almost
all the myasthenia gravis (MG)-associated tumors contain
strikingly more mature CD4 CD45RA cells than those in
non-MG cases. Both CD4 and CD8 mature T cells are
exported to the blood and peripheral immune system9,10; this
infiltration by T cells that have not been properly screened for
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autoreactivity appears to be a key factor predisposing to
thymoma-associated MG (TAMG) and likely other associ-
ated autoimmune diseases in thymoma patients.11,12 To ex-
plain the particular focus on muscle targets, others have
hypothesized some bias in selection, or even active autoim-
munization, of T cells developing within or circulating
through thymomas of types AB, B2 to B3 or A, respectively
(reviewed in Ref. 12), in which some TEC do express several
relevant muscle autoepitopes.13–15 Similar autoimmunization
is believed to underlie other paraneoplastic autoimmune syn-
dromes.16
Myasthenia Gravis
MG is a prototypic T cell-dependent autoantibody-
mediated disease, with well-defined patient subgroups (Fig-
ure 2). In most MG patients, the characteristic fatigable
muscle weakness is clearly caused by autoantibodies to the
acetylcholine receptor (AChR) in its native conformation,
and only rarely by autoantibodies to other autoantigens.17,18
In other subgroups without thymomas, MG onset is before
age 45 in early-onset MG (EOMG), or after that in late-onset
MG (LOMG). In 80% of EOMG patients, the thymus
shows “lymphofollicular hyperplasia” with characteristic
lymph node-like infiltrates; their germinal centers are focused
on rare muscle-like myoid cells,19 the only cells outside
muscle that express intact AChR. There is also ongoing
production of anti-AChR antibodies in situ.20 By contrast, in
LOMG, the thymus is apparently normal-for-age (involuted,
not inflamed), but there are intriguing serological parallels
with TAMG (see below).
Thymoma-Associated MG
TAMG is a distinct MG subgroup: the risk of MG
increases progressively with WHO type from A (20%)
AB to B1 B2 to B3 (60%).11 TAMG patients almost
always have anti-AChR autoantibodies and these are typi-
cally not produced within thymomas but rather in the adjacent
thymic remnant21 or, hypothetically, lymph nodes and bone
marrow. In addition, already at diagnosis, thymoma patients
show an almost unique spectrum of additional autoantibodies:
to striational muscle autoantigens (Figure 2), especially titin
(in 90% of TAMG patients), ryanodine receptors (in 50%);
type I interferons, IL-12 (in 50%) and, rarely, several
Th17-related cytokines (see below) (Table 1).22,23
Interestingly, autoantibodies to titin, ryanodine recep-
tors, type I interferons, and IL-12 are also found in lower
proportions of LOMG patients (without thymomas) but al-
most never in EOMG.24 Further, patients with LOMG and
TAMG share several genetic associations, e.g., in the IL10,
Fc2a, TNFB, and TNFA genes,25,26 also, expansions of
naive CD8 T cells in the blood,9,27 suggest parallel (al-
though probably not identical) defects in central tolerance
induction. The similarities are even more striking in the
antititin subgroups of TAMG and LOMG.25–30
The reasons for the serological overlap between TAMG
and LOMG, and for its major focus on muscle autoantigens,
are unknown. In theory, some LOMG patients might have
already rejected occult thymomas before diagnosis; however,
that would predict that these autoantibodies should occur
together much more than they apparently do. Alternatively, it
might result from the absence or rarity of thymic myoid cells
in thymomas (TAMG) or involuted (LOMG) thymuses, if
they supply muscle autoantigens to tolerogenic DCs in the
normal thymus.12 That implies continuing thymopoiesis even
into old age; if that does occur, the autoantigens expressed by
TEC might bias T cell selection there, as also suspected in
thymomas. In addition, two other features of virtually all
MG-associated thymomas might contribute to autoimmuni-
zation: first, defective generation of FoxP3 regulatory T-
cells within thymomas31 and, second, absence of AIRE
neoplastic TEC24 and remarkable parallels of TAMG with
monogenic autoimmune diseases.
Autoimmune Regulator
AIRE, the Autoimmune Regulator normally promotes
expression of various TRAgs by occasional mTECs, e.g.,
thyroglobulin (Figure 3) and insulin.21 This “promiscuous
expression” of 1000 different TRAgs allows them to delete
autoaggressive T cells.32 To achieve this low-level ectopic
expression, AIRE uses a remarkable variety of molecular
FIGURE 1. Characteristic histology of the main WHO-de-
fined thymomas that are commonly associated with myas-
thenia gravis (MG) and/or other autoimmune diseases.
a,Type A thymoma; b, type AB thymoma; c-e, type B1 thy-
moma, H&E: lighter medullary area (med) with a single Has-
sall’s corpuscle (HC) sharply separated from darker cortical
(cort) area (c); AIRE medullary thymic epithelial cells
(brown nuclei) adjacent to HC (d); desmin-positive myoid
cells (brown) in the medullary area of a type B1 thymoma
(e). f, Type B2 thymoma; g, Type B3 thymoma. H&E (a-
c,f,g); immunoperoxidase (d,e). Reprinted with permission
from Autoimmunity.12
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FIGURE 2. Correlation of myas-
thenia gravis (MG) subtypes with
thymus/thymoma histology, fre-
quency of AIRE medullary thymic
epithelial cells (mTECs), and char-
acteristic autoantibodies to acetyl-
choline receptor (AChR); the stria-
tional muscle antigen titin; the
sarcoplasmic reticulum calcium
channel ryanodine receptor, RyR;
and various cytokines (different in-
terferon-alpha subtypes; IFNs; in-
terleukin 12, IL-12). EOMG, early-
onset MG ( disease onset 45
years of age); LOMG, late-onset
MG (MG without thymoma and
onset at 45 years or later); TAMG,
thymoma-associated MG. H&E-
stained sections: EOMG and LOMG
(100); thymoma (400). The
thymoma represents a characteris-
tic WHO type B2 thymoma (B2).
TABLE 1. Contrasts and Parallels Between Patients With Either APECED (With Germ Line AIRE Mutations) or
AIRE-Negative Thymomas
Organ-Specific Autoimmunity
APECED Thymoma
Prevalence of Clinical
Manifestations
Autoantigen
Targeted Prevalence
Autoantigen
Targeted Prevalence
Endocrine
Parathyroid 90% (HP) NALP-5 45%a
Adrenal cortex 80% (AF) 21-OH 66%b All rare
Gonads 10–20% (HG) SCC 50%b
Pancreatic  cells 5–10% (DM) GAD65 37%b
Ectodermal
Melanocytes 20% (VI) AADC 50%b All rare
Hair follicles 30% (AP) TH 40%b
Muscle None reported
Motor endplate striations All rare or absent AChR (MG) 100%c
Titin (MG) 90%c
RyR (MG) 50%c
Cytokines
Type I interferons IFN- 95% 70%c
IFN- 99% 60%c
IL-12 IL-12 0% 50%c
Th17 series CMC  90% IL-17A 45% 5–10%c
IL-17F 75% 5–10%c
IL-22 90% 5–10%c
a Of all APECED patients (50% of those with hypoparathyroidism).67
b Of all APECED patients.68
c Of thymoma patients with associated MG.23,51
AIRE, autoimmune regulator; APECED, autoimmune polyendocrinopathy candidiasis ecodermal dysplasia; HP, hypoparathyroidism; AF, adrenocortical
failure; HG, hypogonadism; DM, diabetes mellitus; VI, vitiligo; AP, alopecia; CMC, chronic mucocutaneous candidiasis; NALP-5 (NACHT leucine-rich-
repeat protein-5); 21-OH, 21-hydroxylase; SCC, side-chain cleavage enzyme; GAD65, glutamic acid decarboxylase 65; AADC, aromatic L-amino acid
decarboxylase; TH, tyrosine hydroxylase; AChR, acetylcholine receptor; RyR, ryanodine receptor; MG, myasthenia gravis.
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mechanisms.33–35 In addition, it promotes apoptosis of termi-
nally mature mTECs36 (see sections Could AIRE deficiency
in thymomas play a role in paraneoplastic MG? and Could
AIRE deficiency have an oncogenic impact on the develop-
ment of thymomas?) and thus facilitates tolerogenic “cross-
presentation” of mTEC-derived TRAgs by DCs.37 Further-
more, it can also promote deletion of T cells reactive against
some AIRE-independent “bystander” TRAgs,38 possibly by
“creating a tolerogenic climate” by alterations in autoantigen
processing or function of thymic DCs.
The relevance of AIRE for central tolerance in humans
was first highlighted by patients with mostly recessive AIRE
mutations. 39 The resulting multiorgan autoimmune syndrome
is termed “autoimmune polyendocrinopathy candidiasis ec-
todermal dystrophy (APECED).” Clinically, it is extremely
variable in both humans and Aire/ mice, likely because of
differences in genetic background.37 The main symptoms in
humans are chronic muco-cutaneous candidiasis (CMC), usu-
ally followed by autoimmunity that most often targets the
parathyroid glands and adrenal cortex—the diagnostic triad;
also ectodermal tissues, and/or gut, but rarely neuromuscular
structures can be involved.40 In Aire/ mice, the autoim-
mune features result from thymopoiesis in the absence of
Aire mTEC, exactly as we hypothesized in thymomas.
However, the autoantibody repertoires show only limited
overlap between APECED and TAMG, although the very
similar autoantibodies against cytokines found in many
APECED and TAMG patients are striking exceptions (Table
1), as discussed in section Restricted but significant overlap
between TAMG and APECED. It is still not clear why AIRE
deficiency in APECED mainly affects endocrine and ectoder-
mal targets while largely sparing neuromuscular antigens.
AIRE IN THYMOMAS
Defective expression of AIRE in nearly all thymomas
(except for 60% of the rare B1s) has implications for the
classification of thymomas, for the establishment of thymo-
ma-related biomarkers, for autoimmune predisposition, and
hypothetically for the transformation of mTEC.
AIRE Expression is Lacking in 95% of
Thymomas
There are controversial proposals to “simplify” the
WHO classification of thymomas by “lumping together” type
A, AB, B1 thymomas.41 However, we consider that type B1
is entirely different. It is the only one to show any AIRE
mTEC (Figure 3).24 In addition, type B1 thymomas show the
most obvious “organotypic” features among all thymoma
subtypes, including (a) the most clear-cut cortico-medullary
differentiation among all thymoma subtypes, and frequent
(although variable) Hassall’s corpuscles; (b) thymopoiesis
most similar to that in the normal thymus; (c) myoid cells in
medullary islands in some (but not all) cases, although at
lower frequencies than in non-neoplastic thymus; (d) minimal
genomic gains and losses.2,24 To us, these unique features
taken together argue strongly for retaining the B1 distinction
(although in our relatively small series studied so far, AIRE
and AIRE B1 thymomas have not shown different autoim-
mune susceptibility).
Restricted But Significant Overlap between
TAMG and APECED
We believe that a key feature common to APECED and
thymomas is the absence of AIRE, especially as the T cells
newly generated in/exported by thymomas clearly do make
substantial contributions to the peripheral pool.9,10 Hence,
one might expect close similarities in the organs and autoan-
tigens targeted in these two syndromes. In fact, the similari-
ties are very limited.24 Classic APECED manifestations are
rare in thymoma patients, although some of the autoantibod-
ies/disorders have been noted.12,42 Neither MG and anti-
AChR antibodies nor most other neuroimmune conditions
have been reported in APECED; moreover, pure red cell
aplasia or Good syndrome (B-cell deficiency and hypogam-
maglobulinemia) are virtually unknown in APECED pa-
tients.40 Nevertheless, we should remember that 1000
APECED patients have been studied in total, so weak asso-
ciations cannot yet be excluded.
In striking contrast, almost all APECED patients have
neutralizing antibodies to the IFNs, just like those in
TAMG, and especially IFN- (Table 1).6,43 Other autoanti-
bodies neutralizing Th17-associated cytokines are very prev-
alent in APECED, particularly in the patients with CMC
(90%) but also in rare thymoma patients, mostly with
Candida infections. Thus, their CMC seems to have an
autoimmune basis after all. These autoantibodies apparently
affect APC function (anti-IFNs),44 TH1 polarization of naive
T-cells (anti-IL-12 antibodies)45 and defense against CMC (anti-
IL-17F and IL-22).23 Nevertheless, life-threatening infections
are surprisingly uncommon in both APECED and TAMG pa-
tients and are largely restricted to a minority of thymoma
patients with autoimmune hypogammaglobulinemia.46
The rarity of infections in the other thymoma patients—
despite immunosuppressive drug therapy for MG—is likely
due to thymoma development in adulthood, by when TAMG
patients are already well endowed with pathogen-specific
memory T-cells. Similarly, they might, hypothetically, be
protected from APECED-type autoimmune diseases24 by (a)
FIGURE 3. AIRE expression in the normal thymus. a, Ex-
pression of AIRE (blue) in the nucleus of one of the pancy-
tokeratin-expressing (green; antibodiy AE1/AE3) medullary
thymic epithelial cells (mTECs). b, “Promiscuous” expression
of thyroglobulin (green) in one of the AIRE-expressing
mTECs (blue nuclei). Immunofluorescence (400).
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robust AIRE-dependent peripheral tolerance established early
in life47 and (b) AIRE expression in the residual thymus and
even in tolerogenic stromal cells in peripheral lymph nodes.48
Could AIRE Deficiency in Thymomas Play a
Role in Paraneoplastic MG?
As described above, the thymopoiesis in the disorga-
nized, myoid cell-deficient environment of almost all MG-
associated thymomas could explain the preferential autoim-
munity against muscle antigens in thymoma patients.12,24 The
absence of AIRE might contribute to explain this as well.24
The resulting nontolerized T helper cells emigrate from
thymomas as CD4CD45RA naive T cells9,10—ready (hy-
pothetically) to help autoreactive B cells to respond to AChR
and other autoantigens in the periphery. Notably, Stro¨bel et
al.7 found a lower—or greatly delayed—risk of MG in
patients whose thymomas generated fewer CD4 T cells, and
they proposed that impaired negative selection plays a key
role in TAMG.7,49,50 However, thymopoiesis may not be
absolutely necessary as both MG and autoantibodies to
AChR, IFNs and IL-1251 equally occur in rare patients with
type A thymomas that have no apparent thymopoietic activ-
ity.8,52 More specific biases in selection, or even active
autoimmunization, may also contribute to the responses to
cytokines. Consistently with that, antibody titers increase
markedly when these tumors recur,53 and there is ongoing
production of IFN and IL-12 antibodies in the thymomas.21
We therefore believe that in these (and probably other)
thymomas: (a) IFN-producing macrophages and DC could
prime recirculating T-cells; indeed, we have noted activated
CD25 mature T helper cells in an MG type A thymoma8;
(b) AIRE-deficiency creates a milieu in AIRE thymomas—
and APECED thymuses—where autoantigen expression is
“dangerously” autoimmunogenic; for example, AIRE DCs
were found (by some but not all authors) to have augmented
antigen-presenting capacity37,54; (c) the locally abundant
IFN-s might autoimmunize within both thymomas and
AIRE-mutant APECED thymi; (d) the autoantigens available
determine the responses evoked; abundantly expressed intact
IFNs, which are small single-chain molecules, might immu-
nize both local T helper cells and recirculating B-cells in
thymomas, eliciting the autoantibody production observed
there against IFN and IL-12 but not AChR21; (e) the
isolated AChR subunits expressed by thymoma TEC can
prime T helper cells only against linear epitopes in situ,
and these T cells must subsequently induce B-cell re-
sponses in sites where complete, native AChR is available,
e.g., in myoid cells in the adjacent non-neoplastic thymus
(where lymphoid follicles are common in TAMG) or in
muscle-draining lymph nodes.12,55
We also predict (f) endocrine and ectodermal biases in
the repertoire of TRAgs expressed by AIRE-mutant mTEC in
APECED; (g) that early thymectomy in young patients
should help to prevent development of later autoimmune
manifestations.
Autoantibodies as Biomarkers for Thymoma
Antititin autoantibodies are almost specific and highly
sensitive biomarkers for both MG and MG thymomas
(sensitivity, 70–90%) and also for LOMG, particularly with
onset after 60 years of age.53 By contrast, the anti-IFN2
autoantibodies that are almost diagnostic of APECED are
more prevalent in TAMG (70%) and non-MG thymoma
patients (50%) than in LOMG (20–30%). Notably, the anti-
cytokine autoantibodies do not cosegregate with any partic-
ular thymoma subtype.51 Therefore, titin antibodies have
limited use in predicting the presence of a thymoma, unless
the patient is younger than 60, but careful titration of IFN2
and IL-12 antibodies may help in diagnosing thymoma re-
currences.53
Defective AIRE Expression—A Hint of Epithelial
Immaturity?
The molecular basis underlying the defective AIRE
expression in most thymomas is enigmatic. We tested for a
range of signaling molecules (related to TNF) that are known
to be essential for inducing Aire expression in mice, includ-
ing TRAF6, RelB, RANK, RANKL, LT-, LT-R (reviewed
in Refs. 56,57). However, none of them was significantly
altered in the many AIRE thymomas we tested (Figure 4).
Furthermore, even in AIRE-deficient thymomas, T cell mat-
uration appeared broadly normal,7,9 unlike in patients with
such T cell-intrinsic defects as severe combined immunode-
ficiencies or Omenn syndrome.58,59 Recently, complete T cell
maturation was shown to depend on NF-kappa B signaling
induced by interactions of CD40 and RANK with their
respective ligands and that these signals are delivered by
auto-antigen-specific CD4 thymocytes to mTECs display-
FIGURE 4. a, Normal expression of AIRE and
lymphotoxin- (LT-) in the normal thymic me-
dulla. b, Apparently normal expression (mRNA
and/or protein) of TRAF6, RANK, RANKL, LT-,
and LT--receptor in various thymomas compared
with normal thymus. Beta-actin and GAPDH
served as loading controls. The indicated factors
are known to be required for AIRE expression in
the thymus.56–57
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ing cognate autoantigen-MHC-class-II complexes.57 Thus,
the observed defects in MHC class II expression/inducibility
in the TEC in most thymomas both in situ and in vitro11,60
could also explain their defective AIRE expression, which
might alternatively reflect some maturational block earlier in
TEC development.
Could AIRE Deficiency Have An Oncogenic
Impact on the Development of Thymomas?
Aire deficiency predisposes to marginal zone B-cell
lymphoma in old Aire/ mice, likely because of overstimu-
lation of B-cells by peripheral Aire-deficient DC.61 By con-
trast, thymoma development has not been reported either in
Aire/ mice or in APECED patients, even though AIRE
expression in mTECs,36 and its forced expression in other
epithelial cells,62 supports apoptosis. Although AIRE could
thus formally exert tumor suppressor-like functions in the
thymic medulla, there appears to be redundancy in the main-
tenance of mTEC homeostasis in the normal adult thymus.
Indeed, overexpression of antiapoptotic factors such as bcl-
2,63,64 survivin,65 and XIAP66 is characteristic of thymomas
and thymic carcinomas. Nevertheless, we speculate that ab-
sence of AIRE in the setting of thymoma could contribute to
the combined antiapoptotic mechanisms operating there.
CONCLUSIONS
1. The restriction of AIRE expression to some of the rare
“organotypic” type B1 thymomas is a strong biologic
argument for their separation from other WHO sub-
types.
2. AIRE deficiency in thymomas very rarely leads to the
typical manifestations caused by germ-line AIRE muta-
tions in APECED, except for (a) highly prevalent and
diagnostically useful anti-IFN autoantibodies, and (b)
rare APECED-type anti-TH17 cytokine autoantibodies
that apparently predispose to paraneoplastic candidiasis
in rare thymoma patients.
3. Although AIRE deficiency alone is insufficient to cause
MG in thymoma patients, it might help to create a
“dangerous” milieu in which pre-emigrant thymo-
cytes—in the absence of tolerogenic myoid cells—are
actively autoimmunized against autoantigens (such as
the AChR -subunit) that are aberrantly expressed by
neoplastic thymic epithelial cells.
4. Deficiency of AIRE—which is normally pro-apoptotic
in medullary epithelial cells—might contribute to the
spectrum of tumor-promoting antiapoptotic features of
the neoplastic epithelial cells in most thymomas.
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